Mary Eileen Dolan to Follow-Up Studies
This is a "connection" page, showing publications Mary Eileen Dolan has written about Follow-Up Studies.
Connection Strength
0.387
-
Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clin Cancer Res. 2020 12 15; 26(24):6550-6558.
Score: 0.115
-
Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. Clin Cancer Res. 2019 10 01; 25(19):5913-5924.
Score: 0.106
-
Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2013 Feb; 13(1):35-43.
Score: 0.061
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
Score: 0.028
-
Comparison of vaginal microbiota in gynecologic cancer patients pre- and post-radiation therapy and healthy women. Cancer Med. 2020 06; 9(11):3714-3724.
Score: 0.028
-
Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group. Clin Cancer Res. 2020 06 15; 26(12):2891-2897.
Score: 0.028
-
Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. J Clin Oncol. 2016 08 10; 34(23):2712-20.
Score: 0.021